15.42
2.87%
+0.43
Zai Lab Limited ADR stock is currently priced at $15.42, with a 24-hour trading volume of 181.19K.
It has seen a +2.87% increased in the last 24 hours and a -4.70% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $14.91 pivot point. If it approaches the $15.70 resistance level, significant changes may occur.
Zai Lab Limited ADR Stock (ZLAB) Financials Data
Zai Lab Limited ADR (ZLAB) Revenue 2024
ZLAB reported a revenue (TTM) of $266.72 million for the quarter ending December 31, 2023, a +24.03% rise year-over-year.
Zai Lab Limited ADR (ZLAB) Net Income 2024
ZLAB net income (TTM) was -$334.62 million for the quarter ending December 31, 2023, a +24.51% increase year-over-year.
Zai Lab Limited ADR (ZLAB) Cash Flow 2024
ZLAB recorded a free cash flow (TTM) of -$206.67 million for the quarter ending December 31, 2023, a +47.36% increase year-over-year.
Zai Lab Limited ADR (ZLAB) Earnings per Share 2024
ZLAB earnings per share (TTM) was -$3.50 for the quarter ending December 31, 2023, a +23.91% growth year-over-year.
Zai Lab Limited ADR Stock (ZLAB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Smiley Joshua L | See Remarks |
Apr 04 '24 |
Sale |
15.67 |
1,988 |
31,158 |
28,684 |
Amado Rafael | See Remarks |
Apr 04 '24 |
Sale |
15.67 |
1,952 |
30,594 |
23,532 |
Edmondson Frazor Titus III | Chief Legal Officer |
Apr 04 '24 |
Sale |
15.67 |
1,244 |
19,497 |
26,408 |
Chen Yajing | Chief Financial Officer |
Apr 04 '24 |
Sale |
15.67 |
845 |
13,244 |
9,618 |
Smiley Joshua L | See Remarks |
Apr 03 '24 |
Option Exercise |
15.90 |
7,145 |
113,606 |
30,672 |
Amado Rafael | See Remarks |
Apr 03 '24 |
Option Exercise |
15.90 |
5,391 |
85,717 |
25,484 |
Reinhart Harald | See Remarks |
Apr 03 '24 |
Option Exercise |
15.90 |
5,270 |
83,793 |
53,905 |
Edmondson Frazor Titus III | Chief Legal Officer |
Apr 03 '24 |
Option Exercise |
15.90 |
5,031 |
79,993 |
27,652 |
Chen Yajing | Chief Financial Officer |
Apr 03 '24 |
Option Exercise |
15.90 |
2,500 |
39,750 |
10,463 |
Du Ying | Chairperson & CEO |
Apr 02 '24 |
Sale |
16.15 |
5,787 |
93,466 |
1,107,972 |
Zai Lab Limited ADR Stock (ZLAB) Latest News
Top 5 Health Care Stocks That Are Preparing To Pump In February
Benzinga
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Zacks Investment Research
Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On Thursday
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
Benzinga
About Zai Lab Limited ADR
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.
Cap:
|
Volume (24h):